Humedix (200670) Fundamentals 2026 — P/E 5.6x, Revenue Analysis | SniperIQ
Humedix (200670) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩268.1B, trading at ₩24150.00 on the KOE. This SniperIQ fundamentals page covers Humedix's valuation (P/E 5.6x, P/B 0.9x), profitability (net margin 30.1%), revenue (₩170.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Humedix's market cap?
Humedix (200670) has a market capitalization of approximately ₩268.1B, trading at ₩24150.00 on the KOE. Market cap moves with the live share price.
What is Humedix's P/E ratio?
Humedix's trailing twelve-month P/E ratio is 5.6x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Humedix?
Humedix runs a net profit margin of 30.1%, a gross margin of 44.3%, and an operating margin of 23.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Humedix generate?
Humedix reported revenue of ₩170.1B for fiscal year 2025, with net income of ₩51.8B and earnings per share (EPS) of 5017. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Humedix pay a dividend?
Humedix offers a trailing dividend yield of about 4.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Humedix financially healthy?
Humedix carries a debt-to-equity ratio of 0.00x and a current ratio of 8.03x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Humedix a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Humedix (200670) the key facts are: market cap ₩268.1B, P/E 5.6x, revenue ₩170.1B, 52-week range 23800-77200. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Humedix's full fundamentals live
Get Humedix's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.